★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Novo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Novo Nordisk A/S is a Danish healthcare company focused on diabetes, obesity and rare disease. FY2025 sales were led by Diabetes care (67%), followed by Obesity care (27%) and Rare disease (6%). The defensible company-specific moats are concentrated in diabetes and obesity: semaglutide patent protection, very large API and fill-finish manufacturing investments, and contested obesity-franchise trust. Regulatory approval and reimbursement requirements are industry gates, not a standalone Novo advantage, and the disclosed rare-disease production footprint does not establish a proprietary learning curve. Novo reported diabetes value share down to 30.1% and branded GLP-1 obesity volume share down to 59.6% in MAT November 2025, while Wegovy pill exceeded three million prescriptions by 7 June 2026. Key pressures are Lilly competition, China and other patent expiries, US payer and MFN pricing pressure, capacity execution, and next-generation therapies.
Primary segment
Diabetes care
Market structure
Oligopoly
Market share
30.1% (reported)
HHI: —
Coverage
3 segments · 8 tags
Updated 2026-07-11
Segments
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Revenue
67%
Structure
Oligopoly
Pricing
moderate
Share
30.1% (reported)
Peers
Obesity care
Branded obesity pharmacotherapy (chronic weight management; GLP-1-based anti-obesity medicines)
Revenue
26.6%
Structure
Duopoly
Pricing
moderate
Share
59.6% (reported)
Peers
Rare disease
Rare disease therapeutics (haemophilia, growth hormone, and other rare endocrine/blood disorder treatments)
Revenue
6.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
FY2025 Diabetes care sales: DKK 207,109 million; total FY2025 sales: DKK 309,064 million; revenue share computed as 207,109/309,064. Q1 2026 adjusted Diabetes care sales were DKK 44,936 million, down 18% in DKK and 12% at CER.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Key GLP-1 franchise remains protected by patents and active defense against generics, but international patent expiries and share losses make the moat less durable than pure patent duration suggests.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and settlements accelerating generic/biosimilar entry
- Product-specific patent cliffs (finite duration)
- Adverse litigation outcomes narrowing claims
Leading indicators
- Key patent litigation decisions and settlement terms (timing of generic entry)
- Biosimilar/ANDA pipeline filings and approvals
- Patent expiry timeline changes by jurisdiction
Counterarguments
- Strong IP does not prevent share loss to differentiated competitors (e.g., new GLP-1/GIP classes)
- Payer formularies can shift share even before patent expiry via rebates and preferred placement
Capacity Moat
Supply
Capacity Moat
Strength
Durability
Confidence
Evidence
GLP-1 supply and fill-finish/API capacity remain important constraints; Novo has acquired fill-finish sites and is still investing heavily in API, aseptic, finished-production and packaging capacity.
Capacity Moat moat: definition, examples, and stocks
Erosion risks
- Competitors add large-scale capacity (internal or via CMOs)
- Manufacturing quality issues or regulatory shutdowns
- Technology shifts (new modalities) reducing relevance of existing capacity
Leading indicators
- Drug shortage notifications and backorder duration
- Capex announcements and commissioning milestones
- Fill-finish throughput and product allocation updates
Counterarguments
- Capacity advantages can be competed away with time and capital
- Supply constraints can also cap growth and reduce near-term revenue realization
Obesity care
Branded obesity pharmacotherapy (chronic weight management; GLP-1-based anti-obesity medicines)
FY2025 Obesity care sales: DKK 82,347 million; total FY2025 sales: DKK 309,064 million; revenue share computed as 82,347/309,064. Q1 2026 adjusted Obesity care sales were DKK 20,912 million, up 14% in DKK and 22% at CER.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Wegovy injection and pill benefit from patent protection cited by the company, but the key semaglutide molecule expires earlier in some non-US markets and competition has intensified.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and negotiated early-entry settlements
- Emergence of new drug classes with superior efficacy/safety
- Regulatory reforms weakening exclusivity
Leading indicators
- Semaglutide-related IP litigation updates
- Competing oral or next-gen obesity drug approvals
- Formulary positioning changes vs competitors
Counterarguments
- Even with IP, share can shift to better clinical profiles (efficacy/tolerability) from rivals
- Government/payer pressure can reduce net price independent of exclusivity
Capacity Moat
Supply
Capacity Moat
Strength
Durability
Confidence
Evidence
For GLP-1 obesity drugs, manufacturing (API plus fill-finish) is a gating factor; Novo continues to expand supply chain capacity while competitors also add capacity.
Capacity Moat moat: definition, examples, and stocks
Erosion risks
- Competitor capacity catch-up (internal/CMO)
- Manufacturing reliability and quality risks
- Shift to modalities with different manufacturing constraints
Leading indicators
- Supply constraint disclosures and shipment allocation changes
- Capex pace and new site ramp milestones
- Competitor supply expansion announcements
Counterarguments
- Capacity is not a permanent moat; scale can be purchased over time
- Supply shortages can create customer dissatisfaction and reputational risk
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Novo remains a leading branded obesity franchise and the oral launch broadened adoption, but share declined in 2025 and the demand-side advantage is contested by Lilly and newer mechanisms.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Rapid innovation cycles (new oral entrants, new mechanisms)
- Safety/tolerability events impacting perception
- Aggressive competitor contracting and access wins
Leading indicators
- Global branded obesity market share trend vs Lilly
- Persistence/adherence and discontinuation rates
- Net price evolution (rebates, negotiated prices)
Counterarguments
- Share leadership can be driven by supply/availability, not necessarily brand trust
- Competitors with better outcomes or easier administration can flip prescriber preference quickly
Rare disease
Rare disease therapeutics (haemophilia, growth hormone, and other rare endocrine/blood disorder treatments)
FY2025 Rare disease sales: DKK 19,608 million; total FY2025 sales: DKK 309,064 million; revenue share computed as 19,608/309,064. Q1 2026 adjusted Rare disease sales were DKK 4,215 million, down 9% in DKK and 2% at CER.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Patent status for products with marketing authorisation
Annual report patent table shows Ozempic US/China/Japan/Europe active-ingredient patent expiries.
Novo Nordisk has lost volume market share in the GLP-1 market places
Confirms that patent protection has not prevented competitive share losses.
Novo Nordisk acquired three fill-finish sites
Direct evidence of strategic control over a key injectable-drug bottleneck.
investments in additional capacity for active pharmaceutical ingredient (API) production and fill-finish capacity
Shows ongoing capacity build beyond the 2024 Catalent-site transaction.
to 30.1%.
Direct market share disclosure; use as reported rather than derived.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Patent challenges and settlements accelerating generic/biosimilar entry
- Product-specific patent cliffs (finite duration)
- Adverse litigation outcomes narrowing claims
- Competitors add large-scale capacity (internal or via CMOs)
- Manufacturing quality issues or regulatory shutdowns
- Technology shifts (new modalities) reducing relevance of existing capacity
Leading indicators
- Key patent litigation decisions and settlement terms (timing of generic entry)
- Biosimilar/ANDA pipeline filings and approvals
- Patent expiry timeline changes by jurisdiction
- Drug shortage notifications and backorder duration
- Capex announcements and commissioning milestones
- Fill-finish throughput and product allocation updates
Research NOVOB elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.